Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Journal of Clinical Lipidology
Open Access Publication
Rights and Permissions
Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, Goldberg AC, Gotto AM, Leiter LA, Ray KK, Bloedon LT, MacDougall D, Zhang Y, Mancini GBJ. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022 May-Jun;16(3):286-297. doi: 10.1016/j.jacl.2022.03.001. © 2022 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Laufs, Ulrich; Ballantyne, Christie M; Banach, Maciej; Bays, Harold; Catapano, Alberico L; Duell, P Barton; Goldberg, Anne C; Gotto, Antonio M; Leiter, Lawrence A; Ray, Kausik K; Bloedon, LeAnne T; MacDougall, Diane; Zhang, Yang; and Mancini, G B John, "Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials." Journal of Clinical Lipidology. 16, 3. 286 - 297. (2022).
ICTS (Institute of Clinical and Translational Sciences)
Supplemental material is available for this article at publisher site.